Comprehensive genomic profiling (CGP) to reveal new opportunities and challenges in muscle-invasive bladder cancer (MIBC).

479 Background: MIBC is an aggressive disease and a limited number of patients (pts) will benefit from neoadjuvant chemotherapy (NAC) or immunotherapy. CGP may help identify prognostic factors, predictive biomarkers and targets for therapy. Methods: Hybrid-capture based CGP of treatment-naive tissue samples (n = 205) was performed on 3 cohorts of pts with MIBC: i) PURE-01 cohort (n = 144), treated with neoadjuvant pembrolizumab ii) NAC cohort (n...